WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, has announced that newly published research has reaffirmed that the ARROW Central Venous Catheter (CVC) with ARROWg+ard Blue PLUS® Technology reduces the incidence of catheter-related bloodstream infections (CRBSIs) and reduces direct costs related to treatment of these potentially deadly infections.1
Help employers find you! Check out all the jobs and post your resume.
